'Immunization during ART and ATI for HIV-1 vaccine discovery/development'

Curr Opin HIV AIDS. 2023 Nov 1;18(6):309-314. doi: 10.1097/COH.0000000000000817. Epub 2023 Sep 8.

Abstract

Purpose of review: Explore whether immunization with germline-targeting Env immunogens during ART, followed by ATI, leads to the identification of viral envelope glycoproteins (Envs) that promote and guide the full maturation of broadly neutralizing antibody responses.

Recent findings: The HIV-1 envelope glycoprotein (Env) does not efficiently engage the germline precursors of broadly neutralizing antibodies (bnAbs). However, Env-derived proteins specifically designed to precisely do that, have been recently developed. These 'germline-targeting' Env immunogens activate naïve B cells that express the germline precursors of bnAbs but by themselves cannot guide their maturation towards their broadly neutralizing forms. This requires sequential immunizations with heterologous sets of Envs. These 'booster' Envs are currently unknown.

Summary: Combining germline-targeting Env immunization approaches during ART with ATI could lead to the identification of natural Envs that are responsible for the maturation of broadly neutralizing antibody responses during infection. Such Envs could then serve as booster immunogens to guide the maturation of glBCRs that have become activated by germline-targeting immunogens in uninfected subjects.

Publication types

  • Review

MeSH terms

  • AIDS Vaccines*
  • Antibodies, Neutralizing
  • Broadly Neutralizing Antibodies
  • HIV Antibodies
  • HIV Infections* / prevention & control
  • HIV-1* / genetics
  • Humans
  • Immunization
  • Vaccines*
  • env Gene Products, Human Immunodeficiency Virus / genetics

Substances

  • HIV Antibodies
  • Broadly Neutralizing Antibodies
  • Antibodies, Neutralizing
  • env Gene Products, Human Immunodeficiency Virus
  • Vaccines
  • AIDS Vaccines